witness CSF extraction

PreclinicalBiologic

UUniversity Hospital, Toulouse

witness CSF extraction is one of 6 biologic programs targeting Hydrocephalus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HydrocephalusActive, not recruiting

HydrocephalusPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Hydrocephalus

#DrugCompanyPhaseTrials

Imdur

OOmnivium

Approved

—2

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 3

Rapamycin

MMaastricht Radiation Oncology

Phase 2

1 4

Rapamune

PPrism Pharmaceuticals

Preclinical

1 5

witness CSF extraction

UUniversity Hospital, Toulouse

Preclinical

1 6

Patient Treated With DMARD

UUniversity Hospital, Toulouse

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hydrocephalus1 trial

Cerebrospinal Fluid Proteome in Hydrocephalus

Completed·UUniversity Hospital, Toulouse·N/A·NCT02016352·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for witness CSF extraction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — witness CSF extraction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for witness CSF extraction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Toulouse company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Toulouse

witness CSF extraction

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hydrocephalus1 trial

References

Drug Info

Quick Facts

Related News